THE Therapeutic Goods Administration (TGA) has been advised that shortages of certain hormone replacement therapy (HRT) patches containing estradiol will continue throughout 2026, and has extended the current Serious Scarcity Substitution Instrument (SSSI) for these products to 2027.
Affected products include all Estradot patches (Sandoz) and Estraderm MX 100 (Juno Pharmaceuticals).
The TGA has approved the supply of overseas-registered estradiol-containing transdermal patch products in multiple strengths, and pharmacists can order these alternatives and supply them to patients using existing prescriptions.
However, pharmacists should be aware that not all overseas-registered products are PBS-subsidised when dispensed under the SSSI.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jan 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jan 26
